We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Australia’s main pharma lobby is proposing changes in how its members report gifts to healthcare professionals, but at least one industry expert says the plan’s fine print would allow doctors to opt out. Read More
Drugmakers should consider the effects of price harmonization in the Persian Gulf region when deciding where to launch their products in the global marketplace, a new report concludes. Read More
India’s National Pharmaceutical Pricing Authority asked six manufacturers of generic cancer drugs to submit pricing data in advance of its setting price caps on the products, a move that one industry observer says was expected. Read More
In an effort to dispel a perception that Indian drugs are poorly made, the government is offering whistleblowers a hefty reward for providing information on spurious, adulterated and misbranded products. Read More
Recent media reports of GlaxoSmithKline’s decision to dismiss staff in China for bribes that occurred more than a decade ago are raising new questions about the drugmaker’s involvement in alleged corruption that surfaced last year. Read More
Starting next year, drug companies seeking to market products in Canada will need to provide the regulatory authority with information on proposed names, labels and packages.
Read More
A public-private partnership in the EU plans to spend $4.5 billion over the next decade to boost, by 30 percent, the success of clinical trials on high-priority drugs. Read More
European authorities say there is not enough evidence to conclude that emergency contraceptives lose their effectiveness in women weighing 165 pounds or more, as one manufacturer had cautioned in its product labeling. Read More
The French National Assembly last month approved a proposal that would allow doctors to use less expensive off-label drugs even if an approved therapy exists — sparking cries from European drugmakers that the government is placing cost savings over patient safety. Read More
Pharma is seeking greater clarity around a European Medicines Agency initiative to streamline regulatory approvals of drugs and national coverage decisions via parallel reviews by the EMA and health technology assessment bodies. Read More